NLSP
NASDAQNLS Pharmaceutics Ltd.
Price$1.80-13.15 (-62.93%)
2025-07-302025-10-30
Latest news
25 items- PRNewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological InstituteZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board ("SAB"). Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form POS AM filed by NLS Pharmaceutics Ltd.POS AM - NewcelX Ltd. (0001783036) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by NLS Pharmaceutics Ltd.SCHEDULE 13G/A - NewcelX Ltd. (0001783036) (Subject)
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- SECAmendment: SEC Form 25-NSE/A filed by NLS Pharmaceutics Ltd.25-NSE/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- PRNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of MergerCombined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/ -- NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and Plan of Reorganization, as amended from time to time, dated as of November 4, 2024 (the "Merger Agreement"), by and among NewcelX (f/k/a NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ:NLSPW) ("NLS")), NLS Pharmaceutics (Israel) Ltd. an
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- PRNLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon LabsDOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective ProgramsSupported by Solid Cash Position and Strategic Funding OutlookZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders, and Aexon Labs, a biotechnology company advancing next-generation central nervous system ("CNS") therapeutics, today announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability, cognition, and neuroprotection. AEX-635, one of the lead DOXA compounds, also modulate
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- PRNLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following MergerZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes today announced that the ITOL-102 cell therapy program for Type 1 Diabetes, originally supported through a grant from the Israel-U.S. Binational Industrial Research and Development ("BIRD") Foundation awarded to Kadimastem, will continue under the combined company's development framework following the completion o
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- PRNLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with KadimastemZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it intends to effect a reverse share split of the Company's issued and outstanding common shares, par value CHF 0.03 per share (the "Common Shares"), at a ratio of 1-for-10 (the "Reverse Split"). The Company's Common Shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis at the market open on October 31, 2025, under the new trading symbol "NCEL"
- PRNLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's SharesZURICH and NESS ZIONA, Israel, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced that, following the receipt of Nasdaq's approval for the listing of the Company's common shares and the trading of the Company on the Nasdaq Capital Market after completion of the merger between the Company, NLS Pharmaceutics (Israel) Ltd., and Kadimastem (the "Merger"), for the combined company's shares, all material conditions precedent to the completion of the Merger have been fulfilled or waived by the parties. The closing of the Merger has been set for October 30, 2025 (the "Closing Date"
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- PRNLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell TherapiesThe collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage biotechnology company developing breakthrough cell therapy solutions for severe diseases such as ALS and diabetes, today announced the signing of a Memorandum of Understanding ("MOU") between Kadimastem and TargetGene Biotechnologies Ltd. ("TargetGene"), a pioneer in precision gene-editing technologi
- SECSEC Form POS AM filed by NLS Pharmaceutics Ltd.POS AM - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- PRNLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes, today announced an update regarding the proposed merger (the "Merger"). On October 21, 2025, NLS received an approval letter from the Nasdaq Listing Center for the listing of its common shares and the
- SECSEC Form POS AM filed by NLS Pharmaceutics Ltd.POS AM - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NLS Pharmaceutics Ltd.6-K - NLS Pharmaceutics Ltd. (0001783036) (Filer)
NLSP FAQ
6 questionsWhat does NLS Pharmaceutics Ltd. do?
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and...Where does NLSP stock trade?
NLS Pharmaceutics Ltd. (NLSP) is listed on NASDAQ.What sector and industry is NLSP in?
NLS Pharmaceutics Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NLS Pharmaceutics Ltd. go public?
NLS Pharmaceutics Ltd. (NLSP) completed its IPO in 2021.What companies are similar to NLSP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NLSP side-by-side with any of them on Quantisnow.How can I track NLSP on Quantisnow?
Quantisnow aggregates NLS Pharmaceutics Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NLSP to receive live email and push alerts on every new disclosure.